ObsEva Reports Positive Data from Phase 3 Uterine Fibroids Studies
ObsEva SA (OBSV) announced positive top line data from its PRIMROSE 1 and 2 studies. PRIMROSE 1 met its primary endpoint at week 24 while PRIMROSE 2 data showed that continued treatment with linzagolix for 52 weeks offers sustained efficacy and is well tolerated. The company is now looking to prepare its regulatory submissions.
PRIMROSE 1 and 2 study aimed to evaluate the efficacy and safety of Yselty® (linzagolix) in women with heavy menstrual bleeding due to uterine fibroids. The data from the